Security Snapshot

Esperion Therapeutics, Inc. - COM (ESPR) Institutional Ownership

CUSIP: 29664W105

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

204

Shares (Excl. Options)

174,381,745

Price

$2.74

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / COM
Symbol
ESPR on Nasdaq
Shares outstanding
258,506,508
Price per share
$3.12
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
174,381,745
Total reported value
$477,986,655
% of total 13F portfolios
0%
Share change
+22,430,727
Value change
+$57,034,072
Number of holders
204
Price from insider filings
$3.12
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • ESPR - Esperion Therapeutics, Inc. - COM is tracked under CUSIP 29664W105.
  • 204 institutions reported positions in Q1 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 201 to 204 between Q4 2025 and Q1 2026.
  • Reported value moved from $559,772,067 to $477,986,655.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 204 institutions filings for Q1 2026.

Open SEC Evidence

Security key

29664W105

Latest holder period

Q1 2026

13F holders

204

13D/G owners

3

CIK / CUSIP context first

Open Q1 2026 holders ESPR full holder history Esperion Therapeutics, Inc. SEC filings Esperion Therapeutics, Inc. company facts Esperion Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
ESPR
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WASATCH ADVISORS LP 6.1% +65% $43,206,778 +$23,857,290 15,768,897 +123% Wasatch Advisors LP 31 Mar 2026
Two Seas Capital LP 4.7% -6% $25,836,769 -$543,915 9,749,724 -2.1% Two Seas Capital LP 30 Sep 2025
BB BIOTECH AG 4.9% -2% $8,821,598 -$227,500 9,694,064 -2.5% BB Biotech AG 04 Mar 2025

As of 31 Mar 2026, 204 institutional investors reported holding 174,381,745 shares of Esperion Therapeutics, Inc. - COM (ESPR). This represents 67% of the company’s total 258,506,508 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
57%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 6.9% 17,852,427 +0.96% 0% $48,915,650
WASATCH ADVISORS LP 6.1% 15,768,897 +67% 0.29% $43,206,778
Two Seas Capital LP 4.4% 11,394,833 -4.3% 1.4% $31,221,842
ORBIMED ADVISORS LLC 4.1% 10,570,300 +77% 0.65% $28,962,622
VANGUARD CAPITAL MANAGEMENT LLC 4% 10,433,760 0% 0% $28,588,502
TWO SIGMA INVESTMENTS, LP 3.7% 9,458,779 +99% 0.02% $25,917,054
MARSHALL WACE, LLP 2.7% 7,075,083 +29% 0.02% $19,385,727
STATE STREET CORP 2.7% 7,055,794 +19% 0% $19,332,876
D. E. Shaw & Co., Inc. 2.5% 6,540,785 -5.3% 0.01% $17,921,751
GEODE CAPITAL MANAGEMENT, LLC 2.3% 5,955,739 +3.8% 0% $16,322,581
AIGH Capital Management LLC 1.7% 4,400,000 +10% 2.5% $12,056,000
UBS Group AG 1.7% 4,291,711 +1270% 0% $11,759,289
ARMISTICE CAPITAL, LLC 1.5% 3,930,125 0.36% $10,768,543
PenderFund Capital Management Ltd. 1.5% 3,891,926 -11% 1.7% $10,663,877
Nuveen, LLC 1.4% 3,613,709 +0.04% 0% $9,901,563
VANGUARD PORTFOLIO MANAGEMENT LLC 1.4% 3,532,563 0% 0% $9,679,223
Privium Fund Management B.V. 1.3% 3,299,441 1.9% $9,040,468
MORGAN STANLEY 1.1% 2,735,644 -22% 0% $7,495,664
ROYCE & ASSOCIATES LP 1% 2,626,995 -27% 0.07% $7,197,966
GOLDMAN SACHS GROUP INC 0.93% 2,410,454 -15% 0% $6,604,644
JONES FINANCIAL COMPANIES LLLP 0.83% 2,135,741 +2% 0% $5,851,930
NORTHERN TRUST CORP 0.81% 2,104,008 +5.4% 0% $5,764,982
Voleon Capital Management LP 0.74% 1,916,698 +66% 0.11% $5,251,753
Eversept Partners, LP 0.67% 1,735,963 -55% 0.31% $4,756,539
Velan Capital Investment Management LP 0.67% 1,720,000 +42% 3% $4,712,800

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
49
Latest
Q1 2026
Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 174,381,745 $477,986,655 +$57,034,072 $2.74 204
2025 Q4 151,305,588 $559,772,067 +$165,257,335 $3.70 201
2025 Q3 107,960,329 $286,090,424 +$31,947,033 $2.65 187
2025 Q2 98,221,986 $96,659,560 -$21,194,525 $0.98 161
2025 Q1 111,244,473 $160,207,390 -$24,300,645 $1.44 183
2024 Q4 126,046,299 $277,285,420 +$4,393,183 $2.20 188
2024 Q3 128,986,677 $212,839,069 -$18,982,245 $1.65 181
2024 Q2 136,753,565 $303,582,298 +$17,706,459 $2.22 173
2024 Q1 125,253,343 $335,669,495 +$141,351,114 $2.68 147
2023 Q4 71,634,221 $214,185,830 -$13,154,422 $2.99 127
2023 Q3 77,232,361 $75,678,982 -$1,733,880 $0.98 120
2023 Q2 74,286,796 $103,280,736 -$10,483,186 $1.39 121
2023 Q1 80,929,285 $128,750,548 -$22,081,506 $1.59 161
2022 Q4 73,478,005 $457,748,937 +$39,215,603 $6.23 164
2022 Q3 62,444,882 $418,381,560 +$53,328,619 $6.70 143
2022 Q2 55,366,705 $352,132,262 +$24,287,037 $6.36 128
2022 Q1 51,922,058 $241,219,302 -$10,656,706 $4.64 121
2021 Q4 53,613,124 $268,022,905 +$97,310,967 $5.00 119
2021 Q3 24,797,305 $298,815,522 -$61,530,602 $12.05 133
2021 Q2 28,340,478 $599,385,890 -$18,947,335 $21.15 140
2021 Q1 28,702,213 $805,059,737 -$64,474,348 $28.05 151
2020 Q4 30,878,165 $802,895,778 -$34,208,444 $26.00 152
2020 Q3 31,640,175 $1,176,015,102 -$28,756,691 $37.17 165
2020 Q2 31,971,491 $1,640,380,010 +$123,898,647 $51.31 179
2020 Q1 29,570,957 $916,082,618 +$53,953,340 $31.53 157
2019 Q4 27,848,044 $1,621,473,992 +$45,891,970 $59.63 170
2019 Q3 27,027,940 $990,522,973 -$72,172,854 $36.66 145
2019 Q2 28,447,747 $1,323,221,426 +$216,701,139 $46.52 166
2019 Q1 27,588,882 $1,107,641,121 +$27,039,632 $40.15 160
2018 Q4 26,812,324 $1,233,297,022 -$65,824,574 $46.00 152
2018 Q3 28,254,155 $1,253,898,089 -$106,658,510 $44.37 151
2018 Q2 30,817,874 $1,207,760,885 +$133,006,694 $39.19 151
2018 Q1 26,467,526 $1,914,388,196 +$178,186,545 $72.33 184
2017 Q4 24,011,278 $1,580,908,389 +$28,478,384 $65.84 163
2017 Q3 24,158,062 $1,210,838,699 +$158,389,093 $50.12 150
2017 Q2 20,787,063 $962,036,441 +$142,703,625 $46.28 129
2017 Q1 17,982,623 $634,962,044 +$201,687,554 $35.31 116
2016 Q4 14,790,757 $185,178,042 +$1,997,113 $12.52 96
2016 Q3 14,434,779 $199,910,330 -$703,426 $13.85 98
2016 Q2 14,667,103 $144,916,054 -$27,764,688 $9.88 98
2016 Q1 15,788,626 $266,644,000 -$13,544,152 $16.91 104
2015 Q4 16,427,090 $365,743,034 -$11,898,095 $22.26 111
2015 Q3 16,611,937 $391,855,349 -$215,978,223 $23.59 120
2015 Q2 15,304,049 $1,251,247,346 +$182,794,461 $81.76 150
2015 Q1 12,803,656 $1,185,461,048 +$474,650,240 $92.60 139
2014 Q4 7,779,336 $314,790,098 +$168,789,584 $40.44 82
2014 Q3 3,501,400 $85,642,436 +$3,067,413 $24.46 49
2014 Q2 5,556,294 $88,004,478 +$33,701,269 $15.84 43
2014 Q1 3,430,835 $51,872,345 +$961,180 $15.12 40
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .